Rachel is President and CEO of Caribou Biosciences, a CRISPR gene editing company. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, she was named by Fortune Magazine to the "40 Under 40" list of the most influential young people in business.. She is also a co-founder of gene therapy company Intellia Therapeutics. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
[Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.]